Quince Therapeutics (IRLA) Stock Price, News & Analysis

Company Overview

Quince Therapeutics is a clinical-stage biotechnology company focused on developing treatments for rare diseases with significant unmet medical needs. The company’s primary program is EryDex, an investigational therapy designed to deliver dexamethasone through a patient’s own red blood cells.

EryDex is being evaluated for the treatment of ataxia-telangiectasia, a rare inherited disorder that can cause progressive neurological impairment, immune-system problems and other serious complications. The company’s approach is intended to provide sustained exposure to dexamethasone while potentially reducing some of the side effects associated with conventional steroid treatment.

Quince Therapeutics was formerly known as Cortexyme, Inc. Before its strategic shift toward rare-disease programs, Cortexyme pursued therapies for neurodegenerative diseases, including Alzheimer’s disease. The company is headquartered in California and conducts its clinical development activities through research and medical collaborations. Information about its geographic commercial operations is limited because its principal product remains investigational.

Key Stats

• Today's Range: $30.00 to $34.40
• 50-Day Range: N/A
• 52-Week Range: $15.10 to $909.98
• Volume: 97,999 shs
• Average Volume: 82,475 shs
• Market Capitalization: $33.61 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Hold

Quince Therapeutics Stock Analysis - MarketRank™

Quince Therapeutics scored higher than 20% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 1.4 / 5
• Analyst Rating: Hold

Consensus Rating

Quince Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no strong buy ratings, 1 buy rating, no hold ratings, and 1 sell rating.

Amount of Analyst Coverage

Quince Therapeutics has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.7 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Quince Therapeutics are expected to grow in the coming year, from ($7.49) to ($3.62) per share.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

16.12% of the float of Quince Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Quince Therapeutics has a short interest ratio ("days to cover") of 3.3, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Quince Therapeutics has recently increased by 158.13%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Quince Therapeutics does not currently pay a dividend.

Dividend Growth

Quince Therapeutics does not have a long track record of dividend growth.

News and Social Media

• Score: 3.4 / 5
• News Sentiment: 0.39

News Sentiment

Quince Therapeutics has a news sentiment score of 0.39. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.63 average news sentiment score of companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for Quince Therapeutics this week, compared to 0 articles on an average week.

Search Interest

2 people have searched for IRLA on MarketBeat in the last 30 days.

MarketBeat Follows

1 people have added Quince Therapeutics to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 0.6 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Quince Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

5.60% of the stock of Quince Therapeutics is held by insiders.

Percentage Held by Institutions

30.75% of the stock of Quince Therapeutics is held by institutions.

Company Calendar

• Today: 10/30/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: N/A
• Industry: N/A
• Sub-Industry: N/A
• Current Symbol: NASDAQ:IRLA
• CIK: 1662774
• Web: www.quincetx.com
• Phone: (415) 910-5717
• Fax: N/A
• Employees: 38
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): ($156.71)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$83.98 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: -133.84%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 14.52
• Quick Ratio: 14.52

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($128.18) per share
• Price / Book: -0.26

Miscellaneous

• Outstanding Shares: 1,020,000
• Free Float: 960,000
• Market Cap: $33.61 million
• Optionable: N/A
• Beta: 1.33